Flibanserin Ineffective for Hypoactive Sexual Desire Disorder in Women
Am Fam Physician. 2016 Sep 1;94(5):384a-386.
Is flibanserin (Addyi) a safe and effective treatment of hypoactive sexual desire disorder in premenopausal women?
Flibanserin produces a minimal effect on sexual desire and minimally increases the number of satisfying sexual events in women (less than one-half an event per month increase). Many women will be unable to tolerate the adverse effects. (Level of Evidence = 1a)
To assemble studies for inclusion, these authors searched three trial registries and 13 electronic databases, including the Cochrane Library, with reference lists of retrieved articles to identify randomized studies. They included studies published in any language. Two researchers independently identified the studies for inclusion; data were extracted by one reviewer and checked by another. They included five published and three unpublished studies that enrolled a total of 5,914 premenopausal and postmenopausal women. The overall study quality was low: many women dropped out, some authors shifted end points mid-study, and some authors used the “last observation carried forward.” Benefit was statistically significant but clinically minimal for most outcomes. On average across the studies, treatment, compared with placebo, resulted in one additional satisfying sexual event every two months. Diary scores for sexual desire increased from 1.7 to 2.3 points on a scale of 0 to 84 (four studies), and scores on the female sexual function index increased an average of 0.2 to 0.4 on a scale of 1.2 to 6.0. There was minimal or no change in the women's mean global impression of improvement. Patients who received treatment were twice as likely to drop out because of adverse effects, including dizziness, which was four times more likely in that group.
Study design: Meta-analysis (randomized controlled trial)
Funding source: Self-funded or unfunded
Setting: Various (meta-analysis)
Reference: Jaspers L, Feys F, Bramer WM, Franco OH, Leusink P, Laan ET. Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women: a systematic review and meta-analysis. JAMA Intern Med. 2016;176(4):453–462.
POEMs (patient-oriented evidence that matters) are provided by EssentialEvidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, please see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.
For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.
To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.
This series is coordinated by Sumi Sexton, MD, Associate Deputy Editor.
A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
Dec 1, 2019
Access the latest issue of American Family Physician